Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more
Market Cap & Net Worth: Neuren Pharmaceuticals Limited (NURPF)
Neuren Pharmaceuticals Limited (PINK:NURPF) has a market capitalization of $966.26 Million ($966.26 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #8126 globally and #4167 in its home market, demonstrating a 11.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuren Pharmaceuticals Limited's stock price $7.63 by its total outstanding shares 126639526 (126.64 Million).
Neuren Pharmaceuticals Limited Market Cap History: 2015 to 2025
Neuren Pharmaceuticals Limited's market capitalization history from 2015 to 2025. Data shows change from $4.31 Billion to $966.26 Million (-11.41% CAGR).
Neuren Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuren Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.64x
Neuren Pharmaceuticals Limited's market cap is 4.64 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.09x
Neuren Pharmaceuticals Limited's market cap is 7.09 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.31 Billion | $1.67 Million | -$13.40 Million | 2573.67x | N/A |
| 2016 | $1.96 Billion | $3.15 Million | -$12.01 Million | 620.73x | N/A |
| 2017 | $320.40 Million | $631.00K | $3.29 Million | 507.76x | 97.44x |
| 2018 | $136.77 Million | $13.99 Million | $3.07 Million | 9.78x | 44.51x |
| 2019 | $216.55 Million | $495.00K | -$10.82 Million | 437.48x | N/A |
| 2020 | $121.57 Million | $717.00K | -$9.19 Million | 169.56x | N/A |
| 2021 | $353.32 Million | $3.20 Million | -$7.79 Million | 110.52x | N/A |
| 2022 | $690.19 Million | $14.55 Million | $184.00K | 47.43x | 3751.01x |
| 2023 | $2.15 Billion | $231.93 Million | $157.08 Million | 9.27x | 13.69x |
| 2024 | $1.01 Billion | $216.83 Million | $142.04 Million | 4.64x | 7.09x |
Competitor Companies of NURPF by Market Capitalization
Companies near Neuren Pharmaceuticals Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Neuren Pharmaceuticals Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Neuren Pharmaceuticals Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Neuren Pharmaceuticals Limited's market cap moved from $4.31 Billion to $ 966.26 Million, with a yearly change of -11.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $966.26 Million | -4.03% |
| 2024 | $1.01 Billion | -53.18% |
| 2023 | $2.15 Billion | +211.56% |
| 2022 | $690.19 Million | +95.34% |
| 2021 | $353.32 Million | +190.62% |
| 2020 | $121.57 Million | -43.86% |
| 2019 | $216.55 Million | +58.33% |
| 2018 | $136.77 Million | -57.31% |
| 2017 | $320.40 Million | -83.61% |
| 2016 | $1.96 Billion | -54.59% |
| 2015 | $4.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Neuren Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $966.26 Million USD |
| MoneyControl | $966.26 Million USD |
| MarketWatch | $966.26 Million USD |
| marketcap.company | $966.26 Million USD |
| Reuters | $966.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.